Abstract submissions for the 31st International Workshop on HIV Drug Resistance & Treatment Strategies will open on Thursday, 1 August 2024.


The Organising Committee requires that presenting authors submit their previously unpublished abstracts electronically via this website. Abstract submissions will only be accepted from the presenting author. All correspondence regarding the status of the abstract will be sent only to the presenting author.

To submit an abstract click on the button at the top of the page and follow the steps, which will enable you to provide the presenting author contact information, answer a few questions, and then upload the file containing your abstract. To ensure your abstract retains any special characters or formatting, the abstract must be in Microsoft Word format.

Multiple submissions from the same data set will jeopardize abstract acceptance. The Organising Committee requires submission of a single abstract from the entire group involved in the study.

Each applicant may submit a MAXIMUM of two (2) abstracts. If more than two (2) abstracts are submitted, only the last 2 submissions will be evaluated.

For each accepted abstract, one registration slot will automatically be awarded to the presenting author.


For purposes of review and programming, abstracts are divided into topical categories. Selection of the most appropriate category is important as it determines who reviews your abstract. The Organising Committee reserves the right to reassign your abstract to a more appropriate category.

  • Preclinical Resistance
  • New Resistance Technologies and Interpretations
  • Clinical Implications of Resistance for Treatment and Prevention Strategies
  • Epidemiology of Resistance
  • Strategies to Prevent Spread of Resistance
  • Resistance in Children
  • Modelling Resistance
  • PrEP and Resistance
  • Strategies to Improve Antiretroviral Therapy

  • Clinical Cases (Clinical cases should include a brief description of the case with adequate background information to convince the reviewing panel of the relevance and teaching/learning value brought by the case presentation. Ensure that appropriate consent is obtained and all identifiers are removed.)


The body of the uploaded abstract submission should not exceed 450 words; this limit excludes the title, authors and affiliations. Clearly define all concepts and abbreviations at first use. If English is not your primary language, please attempt to have your abstract reviewed by a native English speaker. To be acceptable, abstracts shall contain a concise statement of the research. It is recommended that the author follow the structured format below:

Title (not included in 450 word limit)

Use a short and concise title that indicates the content of the abstract. Capitalise the first letter of each word except prepositions, articles, and species names. Species names should be spelled out at first use. Italicize scientific names of organisms (example: Staphylococcus aureus). For therapeutic agents, only generic names may be used (no trade names are permitted in abstract titles).

Authors/Affiliations (not included in 450 word limit)

Authors’ names should be entered using initial(s) for the first and middle names followed by the full last name, with presenting author underlined (e.g. AN Author1, AN Author2 and AN Author3).

All author affiliations should be entered as follows:

1 University of London, London, UK; 2 University of Frankfurt, Frankfurt, Germany; and 3 University of Paris, Paris, France.


State the problem under investigation or a hypothesis. For therapeutic agents, only generic names may be used (no trade names are permitted). No figures or tables are allowed.


Explain the experimental methods used. For therapeutic agents, only generic names may be used (no trade names are permitted). No figures or tables are allowed.


List the essential results obtained in summary form, with enough quantitative data to permit evaluation by reviewers. For therapeutic agents, only generic names may be used (no trade names are permitted). Simple figures or tables are allowed.


Summarize the findings. It is unacceptable to use statements such as “the results will be discussed”. For therapeutic agents, only generic names may be used (no trade names are permitted). No figures or tables are allowed.


It is required that presentation of any new, previously unpublished compound at the Workshop includes disclosure of the chemical structure.

The online abstract submission process will require affirmation of the authors’ intention to disclose said chemical structure(s). The purpose of this rule is to ensure presentation of sufficient data to allow for meaningful scientific discourse relevant to new developments in the field of drug discovery, and the rule is based on established practices of other similar international conferences.

Authors who believe there is a compelling reason to be exempted from this rule will have an opportunity to present their rationale for nondisclosure to the Committee during the course of online abstract submission. The Organising Committee will take the arguments into consideration during the abstract review process, but it should be noted that exemptions will be granted only rarely.

Non-disclosure of compound structure(s) without prior permission of the Committee may result in loss of presentation privileges for up to two years for all authors on the abstract in question.


To view a sample abstract, click here.


The Organising Committee (OC) and 4-6 members of the Scientific Committee (SC) will review each abstract. The OC evaluates all submitted abstracts. Members of the SC are selected for abstract categories based upon their individual expertise.

OC and SC members are instructed to review the BLINDED abstracts for the quality and originality of the work and to score them numerically. All authors will be anonymous and the reviewers are instructed to abstain from scoring any abstract on which they are an author/co-author, have a financial or personal conflict of interest, or do not have the appropriate expertise to evaluate.

Scores for each abstract are averaged and the standard deviation is calculated to assess variability. If variability is high, outlier scores are identified and censored. Abstracts with high variability in scores are discussed individually. 


Notifications of acceptance will be sent out on Monday, 10 February 2025.

Upon notification of acceptance of abstract, the presenting author must REGISTER for the Workshop, if they haven’t already done so. Abstract presenters MAY NOT be changed after acceptance without consent of the Organising Committee.


Accepted abstracts will be standardised in font and presentation. Any scientific error that appears in the submitted abstract may appear in the printed abstract.


To apply and upload your abstract, please complete and submit the on-line application form, by following the link at the top of the page.